Irbesartan CAS 138402-11-6 Ubunyulu >99.0% (HPLC) API Factory Antihypertensive
Ubonelelo lwabavelisi, ubunyulu obuphezulu, iMveliso yoRhwebo
| Igama leMchiza | Irbesartan |
| Izithethantonye | I-BMS-186295;SR-47436;Aprovel;iAvapro;2-Butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en- 4-enye;2-Butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-enye |
| Inombolo yeCAS | 138402-11-6 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
| Ifomula yeemolekyuli | I-C25H28N6O |
| Ubunzima beMolekyuli | 428.54 |
| Ukuxinana | 1.30±0.10 g/cm3 |
| Ukunyibilika emanzini | Ayinyibilikiyo emanzini |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Uphawu | IWhite to Off-White Crystalline Powder, Inyibilika kancinane etywaleni nakwi methylene chloride, ayinyibilikiyo emanzini. |
| Ukuchongwa kwe-Infrared Absorption | I-spectrum ye-IR ihambelana ne-spectrum efunyenwe nge-Irbesartan RS |
| Ukuchongwa 2 | Ixesha lokugcinwa kwencopho enkulu kwichromatogram yovavanyo ihambelana ne-Irbesartan RS |
| Ubunyulu / Indlela yokuHlalutya | >99.5% (HPLC) |
| Amanzi | <0.50% |
| Iintsimbi ezinzima | <0.002% |
| Intsalela kwi-Ignition | <0.10% |
| Izinto ezinxulumeneyo | (Nge-HPLC) |
| USP Ukungcola A | <0.20% |
| Nakuphi na Ukungcola Okungaziwa | <0.10% |
| Ukungcola ngokupheleleyo | <0.50% |
| Ukungaguquguquki kwezinto eziphilayo | Iyahlangabezana neemfuno ze-USP |
| Azide eseleyo | <10ppm |
| Izinyibilikisi ezishiyekileyo | (Ngu-GC) |
| I-Ethanol | <5000ppm |
| Toluene | <890ppm |
| Dichloromethane | <3000ppm |
| N, N-Dimethylformamide | <880ppm |
| T-Butyl Methyl Ether | <5000ppm |
| Isivavanyi | 98.0 ~ 102.0% (ibalwe kwisiseko se-anhydrous) |
| Umgangatho woVavanyo | uMgangatho woShishino;Umgangatho we-USP |
| Ukusetyenziswa | API;I-antihypertensive;Kunyango loxinzelelo lwegazi |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma
I-Irbesartan (i-CAS: C) i-angiotensin II receptor antagonist esetyenziswa kakhulu kunyango lwe-hypertension.I-Irbesartan yaphuhliswa yiSanofi Research (ngoku eyinxalenye yeSanofi-Aventis).Ithengiswa ngokudibeneyo nguSanofi-Aventis kunye neBristol-Myers Squibb phantsi kwamagama orhwebo Aprovel, Karvea, kunye neAvapro.I-Irbesartan isetyenziselwa ukunyanga uxinzelelo lwegazi oluphezulu.I-Avapro yasungulwa eJamani, e-UK nase-US ngenxa yoxinzelelo lwegazi.Njengazo zonke i-angiotensin II receptor antagonists, i-irbesartan iboniswa kunyango loxinzelelo lwegazi.I-Irbesartan inokulibazisa ukuqhubela phambili kwe-nephropathy yesifo seswekile kwaye ikwaboniswa ekunciphiseni ukuqhubeka kwesifo sezintso kwizigulane ezinesifo seswekile se-2, uxinzelelo lwegazi kunye ne-microalbuminuria (> 30 mg / iiyure ezingama-24) okanye i-proteinuria.I-Irbesartan inokunciphisa ukulungiswa kombane kwi-myocardium, ngaloo ndlela inciphisa izinga lokufa kwezigulana ezinoxinzelelo lwegazi, lelona chiza lisebenzayo kunyango loxinzelelo lwegazi kunye nesifo sentliziyo.
